Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 21;40(35):4071–4082. doi: 10.1200/JCO.21.02844

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 3. — Kaplan-Meier and multivariable Cox proportional hazard regression analyses of DRFI in patients randomly assigned to 2 years of goserelin, tamoxifen, and the combination of goserelin and tamoxifen, compared with patients randomly assigned to no adjuvant endocrine therapy (control), stratified by genomic risk. (A-C) Patients of low genomic risk and (D-F) patients of high genomic risk. ^aMultivariable analysis adjusted for age, random assignment year, lymph node status, tumor size, tumor grade, PR status, HER2 status, Ki-67 status, and type of surgery. DRFI, distant recurrence-free interval; DRs, distant recurrences; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; ref, reference.